Research programme: erythropoietin long-acting - Bolder BioTechnology
Alternative Names: BBT-009Latest Information Update: 19 May 2020
At a glance
- Originator Bolder BioTechnology
- Class Antianaemics; Erythropoietins; Polyethylene glycols
- Mechanism of Action Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 19 May 2020 Discontinued - Preclinical for Anaemia in USA (Parenteral)
- 28 Dec 2019 No recent reports of development identified for preclinical development in Anaemia in USA (Parenteral)
- 04 Dec 2017 Erythropoietin long-acting is still in preclinical development for anaemia in USA (Bolder Biotechnology pipeline, November 2017)